semaglutide and cardiovascular outcomes in obesity without diabetes journal club 2.4 mg delivered a statistically significant 20% risk reduction major adverse events – REGENHEALTHSOLUTIONS (RHS) Semaglutide, inflammatory markers and cardiovascular

This is the first step towards a personalized plan designed to help you achieve your health goals safely and effectively

Husain M, Birkenfeld AL, Donsmark M, Dungan K, Eliaschewitz FG, Franco DR, et al Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes N Engl J Med 2019 381 84151 29

In the FST, a significant reduction in the total activity score (measured by a computerized program 35 ) was induced by BDNF knockdown in the dDG (Figure 2b)

Lancet 2, 905907

Ignoring it leads to the GI misery that causes many people to consider stopping medication

Rotating Injection Sites to Maximize Treatment Safety A systematic rotation schedule prevents injection-site complications and supports long-term treatment success